Information on new drugs at market entry: retrospective analysis of health technology assessment reports versus regulatory reports, journal publications, and registry reports

Background When a new drug becomes available, patients and doctors require information on its benefits and harms. In 2011, Germany introduced the early benefit assessment of new drugs through the act on the reform of the market for medicinal products (AMNOG). At market entry, the pharmaceutical comp...

Descripción completa

Detalles Bibliográficos
Autores principales: Köhler, Michael, Haag, Susanne, Biester, Katharina, Brockhaus, Anne Catharina, McGauran, Natalie, Grouven, Ulrich, Kölsch, Heike, Seay, Ulrike, Hörn, Helmut, Moritz, Gregor, Staeck, Kerstin, Wieseler, Beate
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group Ltd. 2015
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4353284/
https://www.ncbi.nlm.nih.gov/pubmed/25722024
http://dx.doi.org/10.1136/bmj.h796

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4353284/
https://www.ncbi.nlm.nih.gov/pubmed/25722024
http://dx.doi.org/10.1136/bmj.h796

Ejemplares similares